Publications by authors named "G Ravasi"
Article Synopsis
- The prevalence of pretreatment drug resistance (PDR) to certain HIV medications is high in Belize, particularly among those with previous treatment exposure, posing a challenge for effective antiretroviral therapy (ART).
- WHO recommends dolutegravir-based ART regimens for their effectiveness and low resistance risk, which is crucial for reaching UNAIDS' target of 95% viral suppression.
- Recent surveys show that while 79.6% of adults achieved viral suppression on ART, only 50% of children and adolescents did, highlighting the need for better support and adherence to treatment.
International migrants, especially those belonging to key populations, face a considerable HIV burden. However, continuity of HIV care for this group is often challenged along the migration route. We assess the available evidence on the existing interventions that aim to strengthen community and health systems to ensure the continuity of HIV care for international migrants.
View Article and Find Full Text PDFMore than 62,000 individuals are currently on antiretroviral treatment within the public health system in Argentina. In 2019, more than 50% of people on ART received non-nucleoside reverse transcriptase inhibitors (NNRTIs). In this context, the second nationwide HIV-1 pretreatment drug resistance surveillance study was carried out between April and December 2019 to assess the prevalence of HIV-1 drug resistance in Argentina using the World Health Organization guidelines.
View Article and Find Full Text PDFThe first nationally representative cross-sectional HIV drug resistance (HIVDR) survey was conducted in Uruguay in 2018-2019 among adults diagnosed with HIV and initiating or reinitiating antiretroviral therapy (ART). , , and genes of HIV-1 were sequenced. A total of 206 participants were enrolled in the survey; 63.
View Article and Find Full Text PDFArticle Synopsis
- A study in El Salvador assessed the prevalence of HIV drug resistance (HIVDR) among individuals starting antiretroviral therapy (ART) and those receiving ART for 12 and 48 months.* -
- Findings showed that 27% of new ART users had pretreatment drug resistance, with viral load (VL) suppression rates of 88.8% at 12 months and 80.5% at 48 months.* -
- The results indicate a need for improvements in ART delivery to address the high drug resistance to efavirenz or nevirapine and the low VL suppression rates in the population.*